NO20030727L - Oral hurtigsmeltende formulering av en cyklooksygenase-2- inhibitor - Google Patents

Oral hurtigsmeltende formulering av en cyklooksygenase-2- inhibitor

Info

Publication number: NO20030727L
Authority: NO; Norway
Prior art keywords: oral fast; cyclooxygenase; granules; blending; inhibitor
Prior art date: 2000-08-18

Application number

NO20030727A

Other languages

English (en)

Other versions

NO20030727D0 (no

Inventor

Trang T Le

Tugrul T Kararli

Mark J Kontny

Srikonda V Sastry

Janaki Ram Nyshadham

Jr Arthur J Pagliero

Original Assignee

Yamanouchi Pharma Tech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-18

Filing date

2003-02-14

Publication date

2003-03-24

2003-02-14 Application filed by Yamanouchi Pharma Tech Inc filed Critical Yamanouchi Pharma Tech Inc

2003-02-14 Publication of NO20030727D0 publication Critical patent/NO20030727D0/no

2003-03-24 Publication of NO20030727L publication Critical patent/NO20030727L/no

Links

239000000203 mixture Substances 0.000 title abstract 5
229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
238000009472 formulation Methods 0.000 title 1
238000002844 melting Methods 0.000 title 1
229940079593 drug Drugs 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 2
108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 2
239000008187 granular material Substances 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
238000002156 mixing Methods 0.000 abstract 2
229920000881 Modified starch Polymers 0.000 abstract 1
239000002202 Polyethylene glycol Substances 0.000 abstract 1
239000000783 alginic acid Substances 0.000 abstract 1
235000010443 alginic acid Nutrition 0.000 abstract 1
229920000615 alginic acid Polymers 0.000 abstract 1
229960001126 alginic acid Drugs 0.000 abstract 1
150000004781 alginic acids Chemical class 0.000 abstract 1
235000012216 bentonite Nutrition 0.000 abstract 1
239000011230 binding agent Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
239000000796 flavoring agent Substances 0.000 abstract 1
235000013355 food flavoring agent Nutrition 0.000 abstract 1
235000003599 food sweetener Nutrition 0.000 abstract 1
239000000314 lubricant Substances 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
235000019426 modified starch Nutrition 0.000 abstract 1
229920001223 polyethylene glycol Polymers 0.000 abstract 1
229920000193 polymethacrylate Polymers 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
150000004760 silicates Chemical class 0.000 abstract 1
239000003765 sweetening agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Physiology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20030727A 2000-08-18 2003-02-14 Oral hurtigsmeltende formulering av en cyklooksygenase-2- inhibitor NO20030727L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22634700P	2000-08-18	2000-08-18
PCT/US2001/025803 WO2002015885A2 (en)	2000-08-18	2001-08-17	Oral fast-melt formulation of a cyclooxygenase-2 inhibitor

Publications (2)

Publication Number	Publication Date
NO20030727D0 NO20030727D0 (no)	2003-02-14
NO20030727L true NO20030727L (no)	2003-03-24

Family

ID=22848576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20030727A NO20030727L (no)	2000-08-18	2003-02-14	Oral hurtigsmeltende formulering av en cyklooksygenase-2- inhibitor

Country Status (20)

Country	Link
US (1)	US20020049233A1 (no)
EP (2)	EP1309316A2 (no)
JP (2)	JP2004506681A (no)
KR (1)	KR20030045035A (no)
CN (1)	CN1638739A (no)
AT (1)	ATE374599T1 (no)
AU (3)	AU8653001A (no)
BR (1)	BR0113293A (no)
CA (2)	CA2420190A1 (no)
CZ (1)	CZ2003422A3 (no)
DE (1)	DE60130801T2 (no)
DK (1)	DK1355631T3 (no)
ES (1)	ES2292614T3 (no)
IL (1)	IL154386A0 (no)
MX (2)	MXPA03001346A (no)
NO (1)	NO20030727L (no)
NZ (2)	NZ524115A (no)
PL (1)	PL360704A1 (no)
PT (1)	PT1355631E (no)
WO (2)	WO2002015885A2 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1423114A4 (en) *	2001-05-04	2006-05-17	Merck & Co Inc	METHOD AND COMPOSITIONS FOR TREATING MIGRAINE
PL369298A1 (en) *	2001-09-26	2005-04-18	Pharmacia Corporation	Intraorally disintegrating valdecoxib compositions
CA2462881A1 (en) *	2001-10-10	2003-04-17	Pharmacia Corporation	Intraorally disintegrating valdecoxib compositions prepared by spray drying process
CA2466030A1 (en) *	2001-11-07	2003-05-15	Pharmacia Corporation	Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
US7838029B1 (en)	2003-07-31	2010-11-23	Watson Laboratories, Inc.	Mirtazapine solid dosage forms
CN101076318A (zh) *	2004-11-04	2007-11-21	默克公司	造粒方法
JP4945917B2 (ja) *	2005-01-19	2012-06-06	大正製薬株式会社	薬物含有コーティング用核粒子
AU2006247065B8 (en)	2005-05-17	2012-07-12	Amicus Therapeutics, Inc.	A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
ATE398451T1 (de) *	2005-08-29	2008-07-15	Teva Pharma	Festes, teilchenförmiges tadalafil mit bimodaler teilchengrössenverteilung
US7811604B1 (en)	2005-11-14	2010-10-12	Barr Laboratories, Inc.	Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
EA200801449A1 (ru) *	2005-12-23	2008-12-30	Лек Фармасьютиклз Д.Д.	Разрывные гранулы
US20100233272A1 (en) *	2007-11-15	2010-09-16	Leah Elizabeth Appel	Dosage forms comprising celecoxib providing both rapid and sustained pain relief
KR20230066482A (ko)	2012-03-07	2023-05-15	아미쿠스 세라퓨틱스, 인코포레이티드	폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
CN104027319A (zh) *	2014-06-25	2014-09-10	万特制药(海南)有限公司	一种塞来昔布分散片及其制备方法
CN114540327B (zh)	2014-09-30	2026-03-24	阿米库斯治疗学公司	具有增强的碳水化合物的高强度酸性α-葡糖苷酶
KR102747683B1 (ko)	2015-12-30	2024-12-31	아미쿠스 세라퓨틱스, 인코포레이티드	폼페병 치료용의 강화된 산 알파-글루코시다제
JP7046003B2 (ja)	2016-03-30	2022-04-01	アミカスセラピューティックスインコーポレイテッド	高ｍ６ｐ組換えタンパク質の選択方法
SG11201808455VA (en)	2016-03-30	2018-10-30	Amicus Therapeutics Inc	Formulations comprising recombinant acid alpha-glucosidase
ES2950808T3 (es)	2017-05-15	2023-10-13	Amicus Therapeutics Inc	Alfa-glucosidasa ácida humana recombinante
US10350171B2 (en)	2017-07-06	2019-07-16	Dexcel Ltd.	Celecoxib and amlodipine formulation and method of making the same
CN108576205B (zh) *	2018-03-22	2022-01-04	湖北省农业科学院农产品加工与核农技术研究所	一种草莓联合干燥的处理方法
CA3119728A1 (en)	2018-11-21	2020-05-28	Tremeau Pharmaceuticals, Inc.	Purified forms of rofecoxib, methods of manufacture and use
JP2020183359A (ja) *	2019-05-09	2020-11-12	日医工株式会社	セレコキシブ含有医薬組成物
US10945992B1 (en)	2019-11-13	2021-03-16	Tremeau Pharmaceuticals, Inc.	Dosage forms of rofecoxib and related methods
CN116194085A (zh) *	2020-09-17	2023-05-30	康特伦英国斯温顿捷迪斯有限公司	基于表面活性剂与高分子量鱼明胶的剂型用于改善流动特性的用途
US11161833B1 (en)	2021-04-09	2021-11-02	Tremeau Pharmaceuticals, Inc.	Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ278678A (en) *	1994-01-31	1998-03-25	Yamanouchi Pharma Co Ltd	Compressed moulded tablet with quick disintegration/dissolution in the mouth, mixture of low and high moldable saccharides as carriers
US5633272A (en) *	1995-02-13	1997-05-27	Talley; John J.	Substituted isoxazoles for the treatment of inflammation
SK74396A3 (en) *	1995-06-13	1997-04-09	American Home Prod	Organoleptically acceptable oral pharmaceutical compositions
SK284330B6 (sk) *	1996-05-17	2005-01-03	Merck & Co., Inc.	Použitie 3-fenyl-4-(4-metylsulfonyl)fenyl)-2-(5H)-furanónu
EP0839526A3 (en) *	1996-10-31	1999-01-07	Takeda Chemical Industries, Ltd.	Solid pharmaceutical preparation with fast buccal disintegration or dissolution
IT1293764B1 (it) *	1997-07-23	1999-03-10	Chiesi Farma Spa	Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
US6465009B1 (en) *	1998-03-18	2002-10-15	Yamanouchi Pharmaceutical Co., Ltd.	Water soluble polymer-based rapidly dissolving tablets and production processes thereof
SA99191255B1 (ar) *	1998-11-30	2006-11-25	جي دي سيرل اند كو	مركبات سيليكوكسيب celecoxib
CA2362816C (en) *	1999-12-08	2007-02-06	Pharmacia Corporation	Valdecoxib compositions
US6316029B1 (en) *	2000-05-18	2001-11-13	Flak Pharma International, Ltd.	Rapidly disintegrating solid oral dosage form
AU2002236120A1 (en) *	2001-02-27	2002-09-12	Ranbaxy Laboratories Limited	Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors

2001
- 2001-08-13 CN CN01814092.0A patent/CN1638739A/zh active Pending
- 2001-08-17 AU AU8653001A patent/AU8653001A/xx active Pending
- 2001-08-17 JP JP2002520808A patent/JP2004506681A/ja not_active Withdrawn
- 2001-08-17 JP JP2002520807A patent/JP2004512274A/ja not_active Withdrawn
- 2001-08-17 BR BR0113293-8A patent/BR0113293A/pt not_active Application Discontinuation
- 2001-08-17 WO PCT/US2001/025803 patent/WO2002015885A2/en not_active Ceased
- 2001-08-17 DK DK01965984T patent/DK1355631T3/da active
- 2001-08-17 WO PCT/US2001/025834 patent/WO2002015886A2/en not_active Ceased
- 2001-08-17 CZ CZ2003422A patent/CZ2003422A3/cs unknown
- 2001-08-17 ES ES01965984T patent/ES2292614T3/es not_active Expired - Lifetime
- 2001-08-17 US US09/932,500 patent/US20020049233A1/en not_active Abandoned
- 2001-08-17 PT PT01965984T patent/PT1355631E/pt unknown
- 2001-08-17 IL IL15438601A patent/IL154386A0/xx unknown
- 2001-08-17 CA CA002420190A patent/CA2420190A1/en not_active Abandoned
- 2001-08-17 CA CA002418730A patent/CA2418730A1/en not_active Abandoned
- 2001-08-17 EP EP01965987A patent/EP1309316A2/en not_active Withdrawn
- 2001-08-17 AU AU2001286530A patent/AU2001286530B2/en not_active Ceased
- 2001-08-17 AU AU2001286533A patent/AU2001286533A1/en not_active Abandoned
- 2001-08-17 EP EP01965984A patent/EP1355631B1/en not_active Expired - Lifetime
- 2001-08-17 NZ NZ524115A patent/NZ524115A/en unknown
- 2001-08-17 MX MXPA03001346A patent/MXPA03001346A/es not_active Application Discontinuation
- 2001-08-17 DE DE60130801T patent/DE60130801T2/de not_active Expired - Fee Related
- 2001-08-17 MX MXPA03001408A patent/MXPA03001408A/es not_active Application Discontinuation
- 2001-08-17 NZ NZ524123A patent/NZ524123A/en unknown
- 2001-08-17 PL PL36070401A patent/PL360704A1/xx not_active Application Discontinuation
- 2001-08-17 AT AT01965984T patent/ATE374599T1/de not_active IP Right Cessation
- 2001-08-17 KR KR10-2003-7002392A patent/KR20030045035A/ko not_active Ceased
2003
- 2003-02-14 NO NO20030727A patent/NO20030727L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1309316A2 (en)	2003-05-14
ES2292614T3 (es)	2008-03-16
CA2418730A1 (en)	2002-02-28
EP1355631A2 (en)	2003-10-29
DE60130801D1 (de)	2007-11-15
DE60130801T2 (de)	2008-06-26
WO2002015886A2 (en)	2002-02-28
CZ2003422A3 (cs)	2003-06-18
JP2004512274A (ja)	2004-04-22
IL154386A0 (en)	2003-09-17
KR20030045035A (ko)	2003-06-09
PT1355631E (pt)	2007-11-29
US20020049233A1 (en)	2002-04-25
WO2002015886A3 (en)	2002-07-25
CN1638739A (zh)	2005-07-13
JP2004506681A (ja)	2004-03-04
NZ524123A (en)	2005-02-25
MXPA03001346A (es)	2003-06-06
CA2420190A1 (en)	2002-02-28
AU8653001A (en)	2002-03-04
AU2001286530B2 (en)	2007-01-25
NZ524115A (en)	2004-10-29
PL360704A1 (en)	2004-09-20
BR0113293A (pt)	2003-06-10
NO20030727D0 (no)	2003-02-14
WO2002015885A3 (en)	2003-08-28
WO2002015885A2 (en)	2002-02-28
MXPA03001408A (es)	2005-06-30
EP1355631B1 (en)	2007-10-03
AU2001286533A1 (en)	2002-03-04
DK1355631T3 (da)	2008-02-04
ATE374599T1 (de)	2007-10-15

Legal Events

Date	Code	Title	Description
2009-03-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20030727D0 (no)	2003-02-14	Oral hurtigsmeltende formulering av en cyklooksygenase-2- inhibitor
TWI256305B (en)	2006-06-11	Oral fast-melt pharmaceutical composition of a cyclooxygenase-2 inhibitor and process for preparing the same
NO20003196D0 (no)	2000-06-20	Umiddelbart smeltende doseringsformulering
IS5526A (is)	2000-06-09	11ß-Halógen-7alfa-setin estratríen, aðferð til framleiðslu á lyfjasamsetningum sem innihalda fyrrnefnd estratríen og notkun þeirra til framleiðslu á læknislyfjum
ZA200206905B (en)	2003-08-26	Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
HUP0400636A3 (en)	2004-09-28	Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
BR9808429A (pt)	2000-05-23	Composição farmacêutica e processo para a sua preparação.
IS6002A (is)	2001-07-13	Pýrazólkarboxýlsýruafleiður, framleiðsla þeirra, lyfjasamsetningar sem innihalda þær
HUP0301932A3 (en)	2007-09-28	Benzophenones as inhibitors of il-1 beta and tnf-alpha, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions
IS2806B (is)	2012-09-15	5-klór-3-(4-metansúlfónýlfenýl)-6'-metýl-[2,3']bípýridínýl á hreinu kristallaformi og aðferð til efnasmíði
ATE232092T1 (de)	2003-02-15	Ein brause-säure-basepaar enthaltende arzneimittel
MY127350A (en)	2006-11-30	Flash-melt oral dose formulations
DK1210119T3 (da)	2005-06-20	Farmaceutiske sammensætninger til oral og topisk administrering
AU2002341555A1 (en)	2003-09-02	Levothyroxine pharmaceutical compositions, methods of making and methods of administration
DE60103276D1 (de)	2004-06-17	Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
NO20054417L (no)	2005-09-23	Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter
AR034435A1 (es)	2004-02-25	Agentes terapeuticos.
HUP0204422A3 (en)	2003-08-28	Calcium dicarboxylate ethers, methods of making the compounds, and pharmaceutical compositions containing them
PL393598A1 (pl)	2011-04-26	Kryształy F bezwodnego aripiprazolu i sposób ich wytwarzania oraz kompozycja farmaceutyczna je zawierająca, farmaceutyczny stały preparat doustny i sposób jego wytwarzania oraz sposób wytwarzania granulek
IL164994A0 (en)	2005-12-18	Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof